Distinct expression of Survivin splice variants in breast carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Survivin, an inhibitor of apoptosis protein, is implicated in various human cancers.
• Three splice variants of Survivin (Survivin-2B, Survivin-deltaEx3, Survivin-3B) possess distinct antiapoptotic properties.
• Limited data exists on the expression of all Survivin splice variants in breast cancer, especially Survivin-3B.

Purpose of the Study:

• To investigate the expression patterns of all Survivin splice variants in breast cancer.
• To determine the association of Survivin variants with clinicopathological features and p53 status.
• To evaluate the impact of neoadjuvant chemotherapy on Survivin variant expression.

Main Methods:

• Analysis of Survivin transcript expression in breast tumor cell lines and carcinomas.
• Correlation of Survivin variant frequency with tumor size, nodal status, tumor grade, and p53 gene mutation status.
• Assessment of Survivin variant expression before and after neoadjuvant chemotherapy.

Main Results:

• All Survivin transcripts were detected in breast tumors, with minimal expression in normal adjacent tissue.
• Proapoptotic Survivin-2B was more frequent in smaller tumors and inversely associated with lymph node positivity.
• Antiapoptotic Survivin-3B was more prevalent in high-grade carcinomas and those with p53 mutations.
• Neoadjuvant chemotherapy led to a significant decrease in Survivin and Survivin-2B expression, but not Survivin-deltaEx3 or Survivin-3B.

Conclusions:

• Survivin splice variants exhibit differential expression in breast cancer, correlating with tumor progression and treatment response.
• Survivin-3B may function as an antiapoptotic factor in breast cancer, potentially regulated by p53.
• The distinct expression patterns suggest potential roles for specific Survivin variants as prognostic or predictive biomarkers.